The Latest
This Week in HIV Research: The Complexities of Alcohol and Substance Use
April 15, 2021: Alcohol and neurocognitive impairment; using hair analysis to measure substance use; integrase inhibitors' impact on verbal learning; hepatocellular carcinoma trends among PLWH.
Traditional Healers Offer a Culturally Competent Approach to HIV Testing Gaps
In sub-Saharan Africa, herbalists and spiritual healers are working closely with researchers to help reduce HIV transmission in rural communities.
CROI 2021 Highlights: New HIV Research With Clinical Impact
Here's a walkthrough of some of the most compelling stories coming out of the year's biggest HIV science meeting to date.
Most Cancer Drug Trials Still Exclude People With HIV. That’s Both Unfounded and Dangerous.
Helping my longtime friend Jeremy find such trials alerted me to this ongoing problem—which will only be reversed if patients, doctors, and trial reviewers keep pushing back on Pharma.
Clinical Trial Data Needs to Reflect the Demographics of HIV, Say Activists
A recent analysis conducted by the AIDS Treatment Activists Coalition revealed that, among HIV drug trial participants, data specific to race and sex were dramatically underreported.
This Week in HIV Research: We Need to Better Serve Our Teens
April 8, 2021: PrEP “contemplation” and uptake among adolescents; adolescent perception of HIV risk; HIV diagnosis rates among transgender people; PrEP and HIV incidence in Scotland.
HIV Data Bites: Recent Advances in Broadly Neutralizing Antibodies for HIV Prevention
While findings from the high-profile AMP studies have excited scientists, they’re only one of a wide range of bNAb avenues currently being pursued.
As CROI 2021 Attests, the PrEP Revolution Is Coming
Analysis from David Alain Wohl, M.D., on new research in on HIV prevention, especially in areas that will expand and transform PrEP options.
Long-Acting ART Is Here. How Do We Make It Work for Our Patients?
Injectable HIV interventions are a game-changing new option for people dealing with pill fatigue, but there are implementation challenges for clinicians to consider.
Broadly Neutralizing Antibodies for HIV? If We Can Do It for COVID ...
David Alain Wohl, M.D., shares his thoughts on broadly neutralizing antibodies for COVID-19—and the extent to which we can hope to see similar developments in HIV.